Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
The laboratory has the capacity to conduct 30,000+ tests in a month ranging from simple routine tests to semi-specialized and specialized tests
This product is based on Osmotic Controlled Release Oral Delivery System technology
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
The joint venture will help both the parties to further develop the high-margin service business
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
40,000 visitors and representatives of more than 80 countries set to visit the show
Subscribe To Our Newsletter & Stay Updated
